Traders should monitor how Xenon allocates the capital, particularly progress in Phase 3 trials for azetukalner; the large cash infusion strengthens the balance sheet but introduces near-term dilution.
Price Chart
Executive Summary
Xenon Pharmaceuticals closed a public offering of 12,236,843 common shares and pre-funded warrants to purchase 877,194 additional shares, raising approximately $747.5 million in gross proceeds. The offering was priced at $57.00 per common share, with pre-funded warrants sold at $56.9999 and an exercise price of $0.0001 per warrant.
Key Financial Metrics
Key Facts
- Xenon raised approximately $747.5 million in gross proceeds from the offering.
- The offering included 12,236,843 common shares and pre-funded warrants for 877,194 additional shares.
- Common shares were priced at $57.00; pre-funded warrants were priced at $56.9999 with a nominal exercise price of $0.0001.
- The underwriters' option to purchase additional shares was fully exercised.
- Proceeds will be used for general corporate purposes, including R&D for azetukalner and other pipeline programs.
- No securities were sold in Canada or to Canadian residents.
Financial Impact
$747.5 million in gross proceeds, resulting in moderate dilution for existing shareholders
Risk Factors
- Dilution from issuance of new shares and potential future exercises of pre-funded warrants.
- Execution risk in clinical development, particularly for the lead asset azetukalner in multiple indications.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3255083 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 2, 2026 13w ago | Press Release | $60.96 $64.19 | ▲ +5.30% | ▲ +5.71% | $38.02 (−37.63%) |
Jun 5, 2026 16w ago | 144 | $51.21 $60.54 | ▲ +18.22% | ▲ +16.59% | $38.02 (−25.76%) |
Jun 3, 2026 17w ago | 8-K | $52.99 $60.96 | ▲ +15.04% | ▲ +16.41% | $38.02 (−28.25%) |
May 7, 2026 21w ago | Press Release | $56.44 $51.73 | ▼ −8.35% | ▼ −8.37% | $38.02 (−32.64%) |
Apr 22, 2026 23w ago | DEFA14A | $55.41 $54.68 | ▼ −1.32% | ▼ −5.95% | $38.02 (−31.38%) |
Apr 19, 2026 23w ago | Press Release | $57.09 $53.71 | ▼ −5.92% | ▼ −10.12% | $38.02 (−33.40%) |
Apr 15, 2026 24w ago | Press Release | $58.88 $55.00 | ▲ +6.59% | ▲ +12.63% | $38.02 (+35.43%) |
Apr 13, 2026 24w ago | 8-K | $59.35 $55.78 | ▼ −6.02% | ▼ −12.31% | $38.02 (−35.94%) |
Apr 7, 2026 25w ago | Press Release | $57.65 $57.40 | ▲ +0.43% | ▲ +10.21% | $38.02 (+34.05%) |
Mar 13, 2026 29w ago | Insider Cluster | $55.23 $58.60 | ▼ −6.10% | ▼ −2.51% | $38.02 (+31.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access